

**Benaroya Research Institute
IBC MEETING MINUTES
Thursday, May 28, 2026
11:00 AM - 01:00 PM
4 North Conference Room / Zoom**

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BSL: Biosafety Level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
RPD: Research Protections Department
BRI: Benaroya Research Institute
BSC: Biosafety Cabinet
SOP: Standard Operating Procedure

VOTING MEMBERS PRESENT:

Adam Lacy-Hulbert, PhD (*IBC Chair, Animal Containment Expert*)
Vivian Gersuk, PhD (*IBC Vice Chair*)
Estelle Bettelli, PhD (*Animal Containment Expert*)
Bernard Khor, MD, PhD (*Affiliated Physician*)
Ken Gordon (*Community Member*)
Alison Cushman (*Community Member*)
Andrew Burich, DVM (*Animal Containment Expert*)
Alice Wiedeman, PhD (*Affiliated Member*)
John Ray, PhD (*Affiliated Member*)
Shared seat: Angela Webb, RN (*Affiliated Member*)
Amir Figueroa, PhD (*Affiliated Member*)

**ALTERNATE VOTING MEMBER(S)
PRESENT:**

None

VOTING MEMBERS ABSENT:

Shared seat: Nadell Knee, MSN (*Affiliated Member*)
Uma Malhotra, MD (*Affiliated Physician*)

ADMINISTRATIVE SUPPORT:

Tessa Woods

OTHERS PRESENT:

Cheryl Weaver, BA, CCRC, CCRA
Sarah Valenti, JD, CIP
Annthea Vining

As of this meeting, the BRI IBC board has 13 active voting members, with one shared seat (12 seats total). To achieve quorum, at least 7 members are required to be present for voting (including experts as necessary).

1. Call to Order by the IBC Chair

For the purposes of voting today, Members were instructed that after each proposal in favor of passing to verbally confirm if in favor, by stating “aye.” Any member abstaining or voting against the proposal should identify himself or herself so the vote count can be accurate. The Chair will not check votes member by member, and if no abstentions or votes against a proposal are taken, the proposal will be assumed to have passed unanimously.

The IBC administrator took roll by recording the names of all attendees.

2. Confidentiality of Panel Proceedings

The members of the Benaroya IBC and the persons employed by the IBC were asked to maintain the confidentiality of the committee's proceedings unless such information was already made available to the public. The Parties shall maintain the confidentiality of the IBC's hearings, deliberations and initial report, and all written submissions to, and communications with, the IBC.

3. Conflict of Interest Notice

The Chair reminded committee members of Virginia Mason Health Systems policies regarding conflict of interest and asked that any member who might have a conflict of interest make it known and abstain from the vote.

4. Review of Draft Minutes from the Previous Meeting**A. April 02, 2026 IBC Meeting Minutes**

John Ray joined the meeting.

IBC Decision and Vote				
A motion was made to approve the meeting minutes as presented. The motion was seconded.				
For: 11	Against: 0	Abstained: 0	Absent: 1	Recused: 0

5. Safety Update

N/A

6. Notification of Administrative Action (03/17/2026 – 05/14/2026)**A. Protocol ID: IBC23-060, Continuing Review**

PI	Title	BSL	NIH Guidelines
Ray, John	Modulation of immune and autoimmune disease progression through disease-associated genetic variants, enhancers, and genes in immune cells.	1, 2	III-D, III-E, III-F

Additional Safety Practices:	n/a
Primary Reviewer(s):	Lacy-Hulbert, Adam
Summary:	No revisions were made. Biosafety training is up to date. Treatment cards and information sheets are available to staff.
Approved on: 04/01/2026	

B. Protocol ID: IBC25-028, Amendment

PI	Title	BSL	NIH Guidelines
Buckner, Jane	Generation of engineered T cells to study Tregs and Tregs	1, 2	III-D, III-E
Additional Safety Practices:	n/a		
Primary Reviewer(s):	Lacy-Hulbert, Adam		
Summary:	Updates were made to personnel. Biosafety training is up to date. Treatment cards and information sheets are available to staff.		
Approved on: 05/07/2026			

7. New Business

A. Protocol ID: IBC26-005, Three-year Renewal

PI	Title	BSL	NIH Guidelines
Long, Alice	Human Immunophenotyping Core	1, 2	III-E
Additional Safety Practices:	Human materials are to be treated as BSL-2 until fixed, then treated as BSL-1.		
Primary Reviewer(s):	Ray, John; Khor, Bernard		
Recused:	Wiedeman, Alice		

Discussion:	The primary reviewers provided the IBC with an overview of the protocol, its design, and its aims. The Application included additional biohazards and their proposed containment levels. - The Committee reviewed the application, conducted a risk assessment, and determined the biocontainment levels for the research proposed met all applicable NIH Guidelines. - The Committee confirmed the facilities, procedures, practices, training and expertise of personnel are adequate for safe work with all biohazards listed. - Biosafety training updates are required - Treatment cards and information sheets are available to staff.
Decision:	The IBC discussed the criteria for approval and required the following modifications: - Minor revisions to the application as outlined in eProtocol comments and per discussion. - Training must be renewed for the relevant study personnel

Alice Wiedeman left the meeting due to her conflict of interest.

IBC Decision and Vote				
A motion was made to approve the protocol after the modifications mentioned in the meeting and in eProtocol are met. The motion was seconded.				
For: 10	Against: 0	Abstained: 0	Absent: 1	Recused: 1

Alice Wiedeman returned to the meeting.

B. Protocol ID: IBC26-001, Vote to Extend Expiration of Protocol

PI	Title	BSL	NIH Guidelines
Ziegler, Steven	Regulation of Immunity and Inflammation	1, 2	III-D, III-E
Additional Safety Practices:	n/a		
Primary Reviewer(s):	n/a		
Summary:	This protocol requires a vote to extend the expiration date to July 31, 2026. Additional time is needed to address upcoming staffing changes. Following this current meeting (05/28/26), the protocol will be assessed for potential review at the July 23, 2026 meeting.		

IBC Decision and Vote				
A motion was made to approve the extension of the protocol. The motion was seconded.				
For: 11	Against: 0	Abstained: 0	Absent: 1	Recused: 0

8. Discussion Items

A. Board members were given a brief demonstration of Cayuse, the system which will be replacing eProtocol.

9. Adjournment

Next meeting JULY 23, 2026, 11:00am, 4 North Conference Room / Zoom

Jul 24, 2026**box** SIGN 31RJ7L1W-1R27896R

Adam Lacy-Hulbert, PhD
IBC Chair

Date

Prepared by:

Jul 24, 2026**box** SIGN 21XY6L4Y-1R27896R

Tessa Woods
Regulatory Specialist II

Date

ecc: Jane Buckner, MD, BRI President
Margaret McCormick, PhD, BRI Institutional Official
Cheryl Weaver, BA, CCRC, CCRA, Director of Research Integrity & Safety
Adam Lacy-Hulbert, PhD, IBC Chair
IBC Office File